B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
ZURA
Zura BioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.0
Score
AI commentary
The available company evidence establishes trial timing and runway, not a recent market-reaction or analyst-revision signal. No reliable 30-day news-tone, social, options, short-interest, or employee-rating measurements were supplied; zeros above denote unavailable data, not neutral readings. The deterministic prior is negative despite strong primary-source context, supporting monitoring rather than conviction buying.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventTibuSHIELD Phase 2 hidradenitis suppurativa readoutHigh impact
Zura reported completed enrollment of 247 participants and expects topline data in Q4 2026. Efficacy and safety remain unproven; the probability and price-impact figures are scenario judgments, not clinical forecasts. [#SEC-8K-2026-08-11]
2026-12-31eventPlanned NEXUS-PMR Phase 2 initiationHigh impact
Following FDA feedback on its proposed development strategy, Zura plans to initiate a polymyalgia rheumatica study by year-end 2026. Starting the study would expand the pipeline, not establish efficacy. [#SEC-8K-2026-08-11]
2027-06-30catalystTibuSURE Phase 2 systemic sclerosis readoutHigh impact
Zura reported completed enrollment of 91 participants and expects topline data in the first half of 2027. This is a separate binary clinical risk. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology